Persistent Epithelial Defect Market Size was approximately USD 220 Million in 2021, estimates DelveInsight

"The Persistent Epithelial Defect market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Persistent Epithelial Defect pipeline products will significantly revolutionize the Persistent Epithelial Defect market dynamics"

The Persistent Epithelial Defect market report provides current treatment practices, Persistent Epithelial Defect emerging drugs, market share of individual therapies, and current and forecasted 7MM Persistent Epithelial Defect market size from 2019 to 2032. The report also covers current Persistent Epithelial Defect treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Key Takeaways from the Persistent Epithelial Defect Market Research Report
• According to DelveInsight estimates, males are more affected with Persistent Epithelial Defect than females in the 7MM.
• The increase in Persistent Epithelial Defect market size is a direct consequence of expected approval of emerging therapies and the increasing awareness of Persistent Epithelial Defect in the 7MM.
• The leading companies working in the Persistent Epithelial Defect Market include Dompe Farmaceutici, OcuNexus Therapeutics/Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, Recordati Rare Diseases/Mimetech, and others.
• Promising Persistent Epithelial Defect Pipeline Therapies in the various stages of development include Oxervate, KIO-201, ST266, Nexagon, and others.
• July 2023: Combanigo Inc. announced a study of Phase 2 clinical trials for KPI-012. The primary objective of the study is to investigate the safety and efficacy of KPI-012 compared to vehicle in participants who have a documented clinical diagnosis of Persistent Epithelial Defect.
• July 2023: Amber Ophthalmics Inc. announced a study of Phase 2 & 3 clinical trials for lufepirsen. This study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCED). The objectives of the study are to evaluate the safety and efficacy of NEXAGON in this population.

Discover more about therapies set to grab major Persistent Epithelial Defect Market Share @ Persistent Epithelial Defect Market Size- https://www.delveinsight.com/report-store/persistent-epithelial-defect-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Persistent Epithelial Defect Overview
Corneal epithelial defects are some of the most common ocular pathologies that present to ophthalmologists. An acute epithelial lesion usually heals over a 7-14 day time frame. These defects are persistent or non-healing when there is no re-epithelialization despite standard therapy. The normal corneal healing process gets disrupted due to defective epithelial adhesion, limbal stem cell deficiency, surface trauma, medications, infections, and several other etiologies.

Persistent Epithelial Defect Epidemiology Segmentation in the 7MM
• Total Persistent Epithelial Defect Incident Cases
• Persistent Epithelial Defect Etiology-specific Incident Cases
• Persistent Epithelial Defect Gender-specific Incident Cases

Download the report to understand which factors are driving Persistent Epithelial Defect Epidemiology Trends @ Persistent Epithelial Defect Epidemiological Insights- https://www.delveinsight.com/sample-request/persistent-epithelial-defect-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Persistent Epithelial Defect Market Insights
Corneal epithelial defects, though seemingly small, require careful attention and effective treatment for optimal healing and prevention of complications. The treatment and management of these defects involve a multifaceted approach that combines innovative techniques and patient-centered care. From the simple yet powerful act of frequent lubrication with eye drops to promote healing, to the implementation of therapeutic bandage contact lenses that serve as guardians of the delicate cornea, every step aims to restore the epithelium's integrity.

Persistent Epithelial Defect Treatment Market
The current approaches include aggressive lubrication, punctal occlusion, bandage soft contact lens, pressure patching, tetracyclines, prophylactic topical antibiotics, and steroids. For the treatment of refractory cases, amniotic membrane grafting, autologous serum, scleral contact lenses, and others have been recommended. The standard medical treatment protocol begins with aggressive lubrication using preservative-free artificial tears and terile ocular ointments. They provide a setting in which the epithelium can reestablish standard structure and function. It is critical to discontinue all concurrent medications that may disrupt or delay re-epithelialization. Many commercial artificial tears contain preservatives, most commonly benzalkonium chloride, to prevent contamination with bacteria and fungi. These preservatives are known to irritate the eyes and, if used frequently, can cause ocular toxicity and epithelial damage. As a result, it is advisable to use preservative-free lubricants.

To know more about Persistent Epithelial Defect Treatment options, visit @ Persistent Epithelial Defect Drugs- https://www.delveinsight.com/sample-request/persistent-epithelial-defect-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Persistent Epithelial Defect Market Landscape
Despite a significant increase in research on Persistent Epithelial Defect, limited therapeutic options are available and lubricant eye drops which are considered as first-line treatment for the Persistent Epithelial Defect are generally insufficient to treat PCED. With increasing awareness and increase in conditions that affect corneal healing there is a need for therapies that can treat Persistent Epithelial Defect. Most of the companies are focusing on Persistent Epithelial Defect space.

Persistent Epithelial Defect Market Size
The Persistent Epithelial Defect market size in Japan is expected to show a positive growth with a significant CAGR mainly due to the launch of upcoming therapy during the forecast period. The Persistent Epithelial Defect market size in the seven major markets is expected to increase by 2032.

Learn more about the Persistent Epithelial Defect Pipeline Therapies in clinical trials @ Chro Persistent Epithelial Defect Market Landscape- https://www.delveinsight.com/sample-request/persistent-epithelial-defect-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Persistent Epithelial Defect Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Persistent Epithelial Defect Companies- Dompe Farmaceutici, OcuNexus Therapeutics/Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, Recordati Rare Diseases/Mimetech, and others.
• Persistent Epithelial Defect Pipeline Therapies- Oxervate, KIO-201, ST266, Nexagon, and others.
• Persistent Epithelial Defect Market Dynamics: Persistent Epithelial Defect Market Drivers and Barriers
• Persistent Epithelial Defect Market Access and Reimbursement, Unmet Needs, and Future Perspectives

Discover more about Persistent Epithelial Defect Drugs in development @ Persistent Epithelial Defect Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/persistent-epithelial-defect-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Persistent Epithelial Defect Executive Summary
3. Persistent Epithelial Defect Competitive Intelligence Analysis
4. Persistent Epithelial Defect Market Overview at a Glance
5. Persistent Epithelial Defect Market Disease Background and Overview
6. Patient Journey
7. Persistent Epithelial Defect Epidemiology and Patient Population
7.5.6.1. Persistent Epithelial Defect Epidemiology Scenario in Japan (2019-2032)
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Persistent Epithelial Defect Unmet Needs
10. Key Endpoints of Persistent Epithelial Defect Treatment
11. Persistent Epithelial Defect Marketed Products
12. Persistent Epithelial Defect Emerging Therapies
13. Persistent Epithelial Defect: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Persistent Epithelial Defect Market Outlook
16. Persistent Epithelial Defect Market Access and Reimbursement Overview
17. Persistent Epithelial Defect KOL Views
18. Persistent Epithelial Defect Market Drivers
19. Persistent Epithelial Defect Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers and acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

This release was published on openPR.